Stralem & Co’s AstraZeneca AZN Stock Holding History

Stralem & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$6K	Hold	56	–	–	﹤0.01%	67
2020 Q1	$5K	Buy	+56	New	+$5.27K	﹤0.01%	70

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Stralem & Co's AZN Position: Q2 2020 in Review

Stralem & Co held its AstraZeneca (AZN) position steady in Q2 2020 at 56 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #67.

Stralem & Co first reported a position in AZN in Q1 2020 and has held it in 2 quarters since. 669 funds tracked by Wall St. Rank hold AZN as of Q2 2020.

Stralem & Co held 56 shares of AstraZeneca worth $6K as of Q2 2020.
Stralem & Co left its AstraZeneca share count unchanged in Q2 2020.
AstraZeneca made up ﹤0.01% of Stralem & Co's portfolio in Q2 2020, its #67 holding.
Stralem & Co first reported a position in AstraZeneca in Q1 2020 and has held it in 2 quarters since.
669 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2020.

Based on Stralem & Co's 13F filing for Q2 2020, filed 20 Jul 2020.